4.3 Article

A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues

Journal

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 77, Issue 11, Pages 1697-1704

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00228-021-03134-9

Keywords

Drug safety; Adverse drug reaction; ADR reporting by patients; SPC; Non-labelled ADR

Funding

  1. Projekt DEAL

Ask authors/readers for more resources

During the study period, a total of 13,515 patient reports were received, including 29,529 ADRs, with serious ADRs (SADRs) accounting for 4.5%. Women were affected in more than two-thirds of ADR reports. The most common patient-reported ADRs were nausea, dizziness, and headache, while arrhythmia, intestinal obstruction, and erectile dysfunction were the most frequent SADRs.
Purpose Reporting of adverse drug reactions (ADRs) by patients is essential for a comprehensive risk-benefit evaluation of drugs after marketing, but only few data are available regarding patient-centred web-based ADR reporting systems. Hence, we aimed to analyze ADRs reported by patients with a particular emphasis on novel drugs and serious ADRs not yet labelled in the respective summary of product characteristics (SPC). Methods All ADR reports received by a web-based, patient-centred platform (www.nebenwirkungen.de) between April 1, 2019, and September 1, 2020, were descriptively analyzed. ADRs and drugs were coded automatically according to MedDRA and ATC classification system. SPC labelling of reported ADRs for novel drugs marketed since 2015 was checked manually. Results In total, 13,515 patient reports including 29,529 ADRs were received during the study period (serious ADRs [SADRs] n = 1,318; 4.5%). Women were affected in more than two-thirds of ADR reports. The most common patient-reported ADRs were nausea, dizziness and headache, whereas arrhythmia, intestinal obstruction and erectile dysfunction were the most frequent SADRs. Ciprofloxacin, levothyroxine and venlafaxine were the compounds most frequently suspected for causing both ADRs and SADRs. Regarding novel compounds, 289 reports including 739 ADRs were received (mainly fatigue, headache and myalgia). Three hundred thirty-one (44.8%) out of those ADRs were not yet labelled in the respective SPC, whereof twelve were SADRs. Conclusion The majority of patient-reported ADRs were non-serious. However, a relevant number of non-labelled even serious ADRs was reported for novel compounds by patients. Despite well-known limitations of patient-reported ADRs, this web-based ADR reporting system contributes to the identification of new ADRs and thus can help to improve patients' safety complementing other pharmacovigilance instruments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available